Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 7/20 | 0.56 |
| ▸ | NPY1R | P25929 | 6/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413803 | 1.00 | NPY4R (0.56) | NPY4RNPY1RNPY2ROPRK1NPY5R | |
| SCHEMBL9197350 | 0.95 | NPY4R (0.62) | NPY4RNPY1RNPY2ROPRK1NPY5R | |
| SCHEMBL8213821 | 0.93 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL8213819 | 0.93 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL7033970 | 0.92 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL3649800 | 0.91 | NPY4R (0.67) | NPY4RNPY1RNPY2ROPRK1NPY5R | |
| SCHEMBL3649802 | 0.91 | NPY4R (0.67) | NPY4RNPY1RNPY2ROPRK1NPY5R | |
| SCHEMBL6565110 | 0.89 | GNPAT (0.53) | NPY4RNPY1RNPY2RACE | |
| SCHEMBL8727951 | 0.86 | MME (0.54) | NPY4RNPY1RNPY2RACE | |
| SCHEMBL1477244 | 0.86 | MME (0.54) | NPY4RNPY1RNPY2RACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025095587-A1 | METHOD FOR PRODUCING HETEROGRAFT USING PEPTIDE-N-GLYCOSIDASE F | 서울대학교병원 | 2025-05-08 | — | — | WO | claimed |
| US-20250011382-A1 | METHOD FOR THE MANUFACTURE OF BIOPHARMACEUTICALS | RICHTER GEDEON NYRT (HU) | 2025-01-09 | — | — | US | claimed |
| CN-116473940-B | CAF-targeted drug-loaded lipid nanoparticle and preparation method thereof | 山东大学 | 2024-05-31 | — | — | CN | claimed |
| CN-116473940-A | CAF-targeted drug-loaded lipid nanoparticle and preparation method thereof | 山东大学 | 2023-07-25 | — | — | CN | claimed |
| CN-116059366-A | Construction of nano-drug carrying p16-siRNA and application of nano-drug in treatment of post-infarction ventricular remodeling | 南京医科大学 | 2023-05-05 | — | — | CN | claimed |
| WO-2022135563-A1 | METHOD FOR SIMULTANEOUSLY INDUCING IMMUNE RESPONSE AGAINST MULTIPLE VIRUSES | 上海市公共卫生临床中心 | 2022-06-30 | — | — | WO | claimed |
| CN-114213548-A | Method for simultaneously inducing immune response against multiple viruses | 上海市公共卫生临床中心 | 2022-03-22 | — | — | CN | claimed |
| EP-3353152-B1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-09-15 | — | — | EP | claimed |
| US-10869942-B2 | Method | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2020-12-22 | — | — | US | claimed |
| US-20180311384-A1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2018-11-01 | — | — | US | claimed |
| EP-3353152-A1 | METHOD | Norsk Medisinsk Syklotronsenter AS (NO) | 2018-08-01 | — | — | EP | claimed |
| WO-2017072200-A1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2017-05-04 | — | — | WO | claimed |
| US-8530620-B2 | Radiolabelling reagents and methods | GE HEALTHCARE LIMITED (GB) | 2013-09-10 | — | — | US | claimed |
| EP-2186782-B1 | Methods for the purification of radiolabelled products using a solid-support scavanger | GE HEALTHCARE LTD (GB) | 2013-04-17 | — | — | EP | claimed |
| EP-2414333-B1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LTD (GB) | 2013-02-13 | — | — | EP | claimed |
| EP-2414333-A1 | RADIOLABELLING REAGENTS AND METHODS | GE Healthcare UK Limited (GB) | 2012-02-08 | — | — | EP | claimed |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | claimed |
| WO-2010114723-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2010-10-07 | — | — | WO | claimed |
| CN-116042723-B | Oncolytic herpes simplex virus vectors expressing immune system-stimulating molecules | 上海复诺康瑞生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-1995011045-A1 | LABELED CHEMOTACTIC PEPTIDES TO IMAGE FOCAL SITES OF INFECTION OR INFLAMMATION | THE GENERAL HOSPITAL CORPORATION (US) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10869942-B2 | Method | MPI, DUT, NT5E | NPY4R 656/4885NPY1R 1081/4885NPY2R 840/4885 |
| US-20180311384-A1 | METHOD | MPI, DUT, NT5E | NPY4R 656/4885NPY1R 1081/4885NPY2R 840/4885 |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | ANPEP, DNPEP, QRFPR | NPY4R 170/4885NPY1R 356/4885NPY2R 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.